Stay updated on Cabozantinib vs Paclitaxel in Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib vs Paclitaxel in Ovarian Cancer Clinical Trial page.

Latest updates to the Cabozantinib vs Paclitaxel in Ovarian Cancer Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedAdded a comprehensive Locations section listing study sites by state (Alabama through Wisconsin) with revision tag v3.3.3.SummaryDifference1%

- Check16 days agoNo Change Detected
- Check23 days agoNo Change Detected
- Check37 days agoChange DetectedThe Publications section wording was updated to note that PubMed entries are automatically filled and may not all pertain to the study, and the Revision label was updated to v3.3.2.SummaryDifference0.0%

- Check44 days agoChange DetectedDeleted the general notice about a lapse in government funding and potential delays in updates. The study details and links on the page remain unchanged.SummaryDifference0.1%

- Check59 days agoChange DetectedCore study details and eligibility criteria appear unchanged; only minor layout/visual adjustments are observed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check87 days agoChange Detected- Added a government funding lapse notice and operational details (affecting perceived reliability and response capabilities). - Updated version to v3.2.0, removing the previous v3.1.0 tag.SummaryDifference1%

- Check94 days agoChange DetectedShift from biology-focused topics to economics and taxes, with an updated revision to v3.1.0 and removal of numerous biology-related subjects (e.g., proteins, neoplasms) replaced by economics-focused content.SummaryDifference0.6%

Stay in the know with updates to Cabozantinib vs Paclitaxel in Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib vs Paclitaxel in Ovarian Cancer Clinical Trial page.